Vascular Biology and Metabolism (VAM)

Overview

The VAM area was created to allow a comprehensive, cooperative and multidisciplinary approach in basic, clinical and epidemiology research. The ultimate goal is the innovation and transfer of solutions in a group of diseases that are closely interrelated and that constitute the leading cause of morbidity and mortality in the world: cardio-cerebrovascular disease, diabetes-metabolic syndrome and renal impairment. The VAM area includes preclinical and clinical research staff from our center, and collaborative work with groups of the highest international prestige. VAM area includes 8 groups: Cardiovascular Pathology, Diabetes and Metabolism, Nephrology, Ophthalmology (focused on retinal vascular disease), CIBBIM-Nanomedicine and Kidney Physiopathology, Medical Molecular Imaging, Neurovascular Diseases, and Research on Aging, Frailty and Transitions in Barcelona. All groups use an integrative tridimensional approach to generate knowledge on the mechanisms of diseases to generate new diagnostic and therapeutic tools.

Publications

281

total

1353

impact factor

4.81

average impact factor

Group Leader: José Raul Herance Camacho

team

group-zoom

zoom

group-download

download

We have been funded by ISCiii again to continue with one of the main research lines of the group focused on the phenotyping organ-specific insulin sensitivity in type 2 diabetes using PET/CT. The objective of this research is to obtain biomarkers, delve into the pathophysiology of insulin resistance in type 2 diabetes and unravel the pathogenic connection between organs in terms of insulin resistance. The molecular isotope therapy unit became a national and international reference unit. For this reason, several clinical trials of theranostic treatments from some pharma companies for application in oncology were started and are ongoing in this period. We have joined the EU-funded RECOGNISED project to identify type 2 diabetic patients with risk of dementia. We are leading all PET/CT imaging tasks of this project. Several studies focused on infectious endocarditis and metabolomics have performed and published during this period.

18

total

75

impact factor

4^.18

average impact factor

SELECTED ARTICLES

Palomino-Schatzlein, Mayneris-Perxachs J, Caballano-Infantes E, Rodriguez MA, Palomo-Buitrago ME, Xiao X, Mares R, Ricart W, Simo R, Herance JR, Fernandez-Real JM.
Combining metabolic profiling of plasma and faeces as a fingerprint of insulin resistance in obesity.
Clin Nutr. 2020 Jul;39(7):2292-2300.
DOI: 10.1016/j.clnu.2019.10.022
IF: 6.36
Palomino-Schatzlein, Lamas-Domingo R, Ciudin A, Gutierrez-Carcedo P, Mares R, Aparicio-Gomez C, Hernandez C, Simo R, Herance JR.
A Translational In Vivo and In Vitro Metabolomic Study Reveals Altered Metabolic Pathways in Red Blood Cells of Type 2 Diabetes.
J Clin Med. 2020 May 27;9(6).
DOI: 10.3390/jcm9061619
IF: 3.303
Paun B, Leon DG, Cabello AC, Pages RM, de la Calle Vargas E, Munoz PC, Garcia VV, Castell-Conesa J, Baleriola MM, Herance JR.
Modelling the skeletal muscle injury recovery using in vivo contrast-enhanced micro-CT: a proof-of-concept study in a rat model.
Eur Radiol Exp. 2020 Jun 3;4(1):33.
DOI: 10.1186/s41747-020-00163-4
IF: 4.72
Roque A, Pizzi MN, Fernandez-Hidalgo N, Gonzalez-Alujas MT, Rios R, Castell-Conesa J, Escobar M, Ferreira-Gonzalez I, Tornos P, Aguade-Bruix S, Cuellar-Calabria H.
Mosaic Bioprostheses May Mimic Infective Endocarditis by PET/CTA: Trust the Uptake Pattern to Avoid Misdiagnosis.
JACC Cardiovasc Imaging. 2020 Oct;13(10):2239-2244.
DOI: 10.1016/j.jcmg.2019.11.019
IF: 12.74
Roque A, Pizzi MN, Fernandez-Hidalgo N, Permanyer E, Cuellar-Calabria H, Romero-Farina G, Rios R, Almirante B, Castell-Conesa J, Escobar M, Ferreira-Gonzalez I, Tornos P, Aguade-Bruix S.
Morpho-metabolic post-surgical patterns of non-infected prosthetic heart valves by [18F]FDG PET/CTA: “normality” is a possible diagnosis.
Eur Heart J Cardiovasc Imaging. 2020 Jan 1;21(1):24-33.
DOI: 10.1093/ehjci/jez222
IF: 4.841

View all publications